Geminii Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.5M

  • Investors
  • 2

Geminii General Information

Description

Developer of a non-invasive wearable device designed to manage blood sugar continuously. The company's device produces robust anti-diabetic effects in animal models that do not cause weight gain, and produces no signs consistent with hypoglycemia, enabling patients to reduce blood sugar and reverse insulin resistance without the use of pills or injectables.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25 South Grand Avenue
  • 2192 Medical Laboratories
  • Iowa City, IA 52242
  • United States
+1 (347)
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Corporate Office
  • 25 South Grand Avenue
  • 2192 Medical Laboratories
  • Iowa City, IA 52242
  • United States
+1 (347)

Geminii Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Geminii Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 03-Dec-2024 $1.5M Completed Generating Revenue
2. Later Stage VC (Series A) 01-Sep-2023 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2016 Completed Startup
To view Geminii’s complete valuation and funding history, request access »

Geminii Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Geminii’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Geminii Patents

Geminii Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222107-A1 Systems and methods for electrical or magnetic stimulation Pending 14-Apr-2025

Geminii Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Geminii Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
InnoVenture Iowa Venture Capital Minority
UIVentures Accelerator/Incubator Minority
To view Geminii’s complete investors history, request access »

Geminii FAQs

  • When was Geminii founded?

    Geminii was founded in 2016.

  • Where is Geminii headquartered?

    Geminii is headquartered in Iowa City, IA.

  • What is the size of Geminii?

    Geminii has 4 total employees.

  • What industry is Geminii in?

    Geminii’s primary industry is Therapeutic Devices.

  • Is Geminii a private or public company?

    Geminii is a Private company.

  • What is Geminii’s current revenue?

    The current revenue for Geminii is .

  • How much funding has Geminii raised over time?

    Geminii has raised $3.6M.

  • Who are Geminii’s investors?

    InnoVenture Iowa and UIVentures have invested in Geminii.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process